Skip to content

A modified surgical technique to prevent rebleed in eye after vitreous removal surgery in diabetic retinal ( inner layer of eye) detachments .

Vitrectomy with 360 degree scleral depression assisted vitreous base shaving to prevent postoperative vitreous cavity hemorrhage in diabetic tractional retinal detachment eyes. - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/12/060848
Enrollment
30
Registered
2023-12-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Vitrectomy with 360 degree scleral depression assisted vitreous base shaving to prevent post-operative vitreous cavity haemorrhage in diabetic retinal detachment eyes: 360 degree sclera

Sponsors

Advanced Eye Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who require vitrectomy for diabetic vitreous hemorrhage with TRD Patients > 18yrs of age Patients willing for preoperative injection of Ranibizumab (parent molecule or biosimilar) Psuedophakic patients. Patients willing for a follow up period of 3 months

Exclusion criteria

Exclusion criteria: Phakic and Aphakic patients Patients with history of prior vitrectomy Patients with combined retinal detachment Patients with neovascular glaucoma and iris neovascularisation. Eyes requiring internal tamponade in the event of intraoperative iatrogenic break formation will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
We will compare the incidence of POVCH in diabetic tractional retinal detachment eyes between group A and group B. Group - patients undergoing vitrectomy with scleral depression assisted vitreous base shaving. Group B - patients undergoing vitrectomy with no Scleral depression assisted vitreous base shaving .Timepoint: Day 1 , day 7 , day 30,day 90

Secondary

MeasureTime frame
We will compare the number of patients requiring any repeat intervention for management of POVCH between group A and group B.Timepoint: Day 1 , day 7 , day 30 , day 90.;We will compare the visual gain at 3 months between group A and group B. Timepoint: Day 1 , day 7 , day 30 , day 90.

Countries

India

Contacts

Public ContactSHILPA SABU

Post graduate institute of medical education and research, Chandigarh

mankoo95@yahoo.com9463001620

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026